Released Nov 14, 2025, after the close
10-Q filed Nov 14, 2025, 45 days after period end · 0001493152-25-023477
Q2 2026 · 10-Q
Revenue$36.32M$36.32M +92.4% vs Q2 2025−9.7% vs Q1 2026
Net Income$13.70M$13.70M N/M vs Q2 2025N/M vs Q1 2026
EPS Diluted$0.01$0.01 N/M vs Q2 2025N/M vs Q1 2026
Gross Profit$14,073,033+71.7%
Operating Income$8,213,746+135.7%
Operating Cash Flowderived$5,104,273+250.4%
Free Cash Flowderived$5,000,939+266.5%
Margins · derived
Gross margin38.7%−4.7 pt vs Q2 2025
Operating margin22.6%+4.2 pt vs Q2 2025
Net margin37.7%+96.2 pt vs Q2 2025
What the release said
The release
Same quarter
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $36.32M | $18.88M | $14.16M | $8.59M |
| Net Income | $13.70M | -$11.04M | $14.93M | $1.52M |
| EPS Diluted | $0.01 | -$0.01 | $0.01 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR